Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  329,597 results for ""RITUXIMAB""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

High-Dose ERT, Rituximab, and Early HSCT in an Infant with Wolman's Disease.

  • Authors : Eskandari SK; From the Department of Metabolic Diseases, Beatrix Children's Hospital (S.K.E., F.B., F.J.S., C.M.A.L.), and the Department of Surgery (S.K.E.), University Medical Center (UMC) Groningen, Groningen, the Division of Pediatrics (E.G.M.R., M.B., P.M.H., C.A.L.) and the Department of Metabolic Diseases (P.M.H.), UMC Utrecht, and the Department of Stem Cell Transplantation, Princess Máxima Center for Pediatric Oncology (E.G.M.R., M.B., C.A.L.), Utrecht, and the Department of Pediatrics, Gelre Hospital, Apeldoorn (D.J.P.) - all in the Netherlands.; Revenich EGM

Subjects: Dietary Fats*/Dietary Fats*/Dietary Fats*/adverse effects ; Enzyme Replacement Therapy*/Enzyme Replacement Therapy*/Enzyme Replacement Therapy*/methods ; Hematopoietic Stem Cell Transplantation*/Hematopoietic Stem Cell Transplantation*/Hematopoietic Stem Cell Transplantation*/methods

  • Source: The New England journal of medicine [N Engl J Med] 2024 Feb 15; Vol. 390 (7), pp. 623-629.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Editorial & Opinion

Persistence of IgG4 as a potential serological marker of disease activity in patients with epidermolysis bullosa acquisita treated with rituximab.

  • Authors : Gordilho JO; Department of Dermatology, Faculdade de Medicina FMUSP, Universidade de São Paulo, Sao Paulo, SP, Brazil.; Miyamoto D

Subjects: Epidermolysis Bullosa* ; Epidermolysis Bullosa Acquisita*/Epidermolysis Bullosa Acquisita*/Epidermolysis Bullosa Acquisita*/diagnosis ; Epidermolysis Bullosa Acquisita*/Epidermolysis Bullosa Acquisita*/Epidermolysis Bullosa Acquisita*/drug therapy

  • Source: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Jan; Vol. 38 (1), pp. e45-e47. Date of Electronic Publication: 2023 Aug Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.

  • Authors : Ip A; Division of Oncology, Hackensack University Medical Center, Hackensack, NJ, USA.; Department of Oncology, Hackensack Meridian School of Medicine, Nutley, NJ, USA.

Subjects: Lenalidomide*/Lenalidomide*/Lenalidomide*/administration & dosage ; Lenalidomide*/Lenalidomide*/Lenalidomide*/adverse effects ; Lymphoma, Mantle-Cell*/Lymphoma, Mantle-Cell*/Lymphoma, Mantle-Cell*/drug therapy

  • Source: Leukemia & lymphoma [Leuk Lymphoma] 2023 Dec; Vol. 64 (14), pp. 2225-2235. Date of Electronic Publication: 2023 Dec 25.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease.

Subjects: Rituximab*/Rituximab*/Rituximab*/adverse effects; Humans ; Retrospective Studies

  • Source: RMD open [RMD Open] 2024 Jan 30; Vol. 10 (1). Date of Electronic Publication: 2024 Jan 30.Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 101662038 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

ALSUntangled #67: rituximab.

  • Authors : Li X; Department of Neurology, Duke University, Durham, NC, USA.; Armon C

Subjects: Amyotrophic Lateral Sclerosis*/Amyotrophic Lateral Sclerosis*/Amyotrophic Lateral Sclerosis*/drug therapy ; Rituximab*/Rituximab*/Rituximab*/therapeutic use; Humans

  • Source: Amyotrophic lateral sclerosis & frontotemporal degeneration [Amyotroph Lateral Scler Frontotemporal Degener] 2023 Aug; Vol. 24 (5-6), pp. 544-547. Date of Electronic Publication: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101587185 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes.

Subjects: MYASTHENIA gravis; RITUXIMAB; MONOCLONAL antibodies

  • Source: Neurological Sciences. Mar2024, Vol. 45 Issue 3, p1233-1242. 10p.

Record details

Read More Add to Saved list
×
Academic Journal

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience.

  • Authors : Chen P; Department of Nephrology, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, China.; Shanxi Genetic Engineering Center for Experimental Animal Models, Taiyuan, China.

Subjects: Glomerulonephritis, Membranous*/Glomerulonephritis, Membranous*/Glomerulonephritis, Membranous*/drug therapy ; Rituximab*/Rituximab*/Rituximab*/adverse effects ; Rituximab*/Rituximab*/Rituximab*/therapeutic use

  • Source: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Feb 15; Vol. 14, pp. 1044782. Date of Electronic Publication: 2023 Feb 15 (Print Publication: 2023).Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series.

  • Authors : Liu L; Department of Nephrology, China-Japan Friendship Hospital, No.2, East Yinghua Street, Beijing, 100029, People's Republic of China.; Lu H

Subjects: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis*/Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis*/Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis*/diagnosis ; Antibodies, Antineutrophil Cytoplasmic* ; Rituximab*/Rituximab*/Rituximab*/adverse effects

  • Source: BMC nephrology [BMC Nephrol] 2023 Feb 08; Vol. 24 (1), pp. 28. Date of Electronic Publication: 2023 Feb 08.Publisher: BioMed Central Country of Publication: England NLM ID: 100967793 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2369

Record details

Read More Add to Saved list
×
Academic Journal

Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments.

Subjects: RITUXIMAB; ENCEPHALITIS; INTRAVENOUS immunoglobulins

  • Source: Neurological Sciences. Nov2022, Vol. 43 Issue 11, p6441-6447. 7p. 1 Color Photograph, 1 Chart, 1 Graph.

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?

Subjects: *PEMPHIGUS vulgaris; *RITUXIMAB; *LYMPHOPROLIFERATIVE disorders

  • Source: Antibodies (2073-4468). Mar2024, Vol. 13 Issue 1, p4. 4p.

Record details

Read Online Read More Add to Saved list
×
  • 1-10 of  329,597 results for ""RITUXIMAB""